La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Journey Medical Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Journey Medical ha un patrimonio netto totale di $11.3M e un debito totale di $22.7M, che porta il suo rapporto debito/patrimonio netto a 201.4%. Le sue attività totali e le sue passività totali sono rispettivamente $65.2M e $53.9M. L'EBIT di Journey Medical è $2.1M rendendo il suo rapporto di copertura degli interessi 2.3. Ha liquidità e investimenti a breve termine pari a $23.9M.

Informazioni chiave

201.4%

Rapporto debito/patrimonio netto

US$22.75m

Debito

Indice di copertura degli interessi	2.3x
Contanti	US$23.91m
Patrimonio netto	US$11.30m
Totale passività	US$53.89m
Totale attività	US$65.19m

Aggiornamenti recenti sulla salute finanziaria

Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

May 06

Recent updates

Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

May 06

Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%

Mar 11

Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues

Jan 18

Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Nov 10

US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results

May 12

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $46.5M ) di DERM superano le sue passività a breve termine ( $34.1M ).

Passività a lungo termine: Le attività a breve termine di DERM ( $46.5M ) superano le sue passività a lungo termine ( $19.7M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: DERM ha più liquidità del suo debito totale.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di DERM si sia ridotto negli ultimi 5 anni.

Copertura del debito: Il flusso di cassa operativo di DERM è negativo, pertanto il debito non è ben coperto.

Copertura degli interessi: I pagamenti degli interessi sul debito di DERM non sono ben coperti dall'EBIT ( 2.3 x copertura).

Journey Medical Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

Journey Medical Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market

Journey Medical Corporation announced delayed 10-Q filing

Recent updates

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Journey Medical Corporation to Report Q2, 2024 Results on Aug 12, 2024

New minor risk - Market cap size

CFO & Corporate Controller recently sold US$51k worth of stock

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Journey Medical Corporation to Report Q1, 2024 Results on May 13, 2024

Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer

Journey Medical Corporation, Annual General Meeting, Jun 25, 2024

New major risk - Share price stability

Consensus EPS estimates fall by 196%

Independent Director recently bought US$104k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Journey Medical Corporation to Report Fiscal Year 2023 Results on Mar 21, 2024

Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting

Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

New minor risk - Profitability

Journey Medical Corporation Announces Resignation of Jeffrey Paley as Member of the Board of Directors

Journey Medical Corporation Announces Successful Completion of Pre-Nda Meeting with the Fda for Dfd-29 to Treat Rosacea

Consensus revenue estimates increase by 26%

Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Journey Medical Corporation to Report Q3, 2023 Results on Nov 07, 2023

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29

Independent Director recently bought US$98k worth of stock

Independent Director recently bought US$89k worth of stock

Executive Chairman recently bought US$223k worth of stock

Journey Medical Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market

Price target increased by 30% to US$6.50

Journey Medical Corporation Announces Impairment Charges for the Second Quarter Ended June 30, 2023

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) on Microbial Flora of Healthy Adult Subjects

Journey Medical Corporation announced delayed 10-Q filing

Journey Medical Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS misses analyst expectations

Journey Medical Corporation Announces CFO Changes, Effective January 27, 2023

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 Mg) for the Treatment of Papulopustular Rosacea

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$7.33

Journey Medical Corporation to Report Q3, 2022 Results on Nov 10, 2022

Consensus EPS estimates fall by 14%

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating Dfd-29 (Minocycline Modified Release Capsules 40 Mg) for the Treatment of Papulopustular Rosacea

Consensus EPS estimates fall by 36%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Journey Medical Corporation to Report Q2, 2022 Results on Aug 09, 2022

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 14%

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane